P49 MAGELLAN-1, PART 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure

oleh: Fred Poordad, Stanislas Pol, Armen Asatryan, Maria Buti, David Shaw, Christophe Hézode, Franco Felizarta, Robert W. Reindollar, Stuart C. Gordon, Stephen Pianko, Michael W. Fried, David E. Bernstein, Joel Gallant, Chih-Wei Lin, Yang Lei, Teresa I. Ng, Tami Pilot-Matias, Jens Kort, Federico Mensa